Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Irvine, David A ^a   Zhang, Bin ^b   Kinstrie, Ross ^a   Tarafdar, Anuradha ^a   Morrison, Heather ^a   Campbell, Victoria L ^a   Moka, Hothri A ^a   Ho, Yinwei ^b   Nixon, Colin ^d   Manley, Paul W ^c   Wheadon, Helen ^a   Goodlad, John R ^e   Holyoake, Tessa L ^a   Bhatia, Ravi ^f   Copland, Mhairi ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BIPHENYL DERIVATIVE; CD34 ANTIGEN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; SONIDEGIB;

ANIMAL; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; DISEASE MODEL; DRUG EFFECTS; HEMATOPOIETIC STEM CELL; HUMAN; LENTIVIRUS; METABOLISM; MOLECULAR LIBRARY; MOUSE; PATHOLOGY; PHARMACOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD34; BIPHENYL COMPOUNDS; DISEASE MODELS, ANIMAL; HEDGEHOG PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SPLEEN;

EID: 84969248895     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25476     Document Type: Article

References (59)

1. Apperley, J. F. Chronic myeloid leukaemia. Lancet 385, 1447-1459 (2015).
2. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
3. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine 355, 2408-2417 (2006).
4. Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology 11, 1029-1035 (2010).
5. Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24, 1719-1724 (2010).
6. Chu, S. et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118, 5565-5572 (2011).
7. Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118, 3657-3660 (2011).
8. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
9. Jorgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C. and Holyoake, T. L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109, 4016-4019 (2007).
10. Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532-4539 (2006).
11. Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Journal of Clinical Investigation 121, 396-409 (2011).
12. Kumari, A., Brendel, C., Hochhaus, A., Neubauer, A. and Burchert, A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 119, 530-539 (2012).
13. Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501-1510 (2012).
14. Packer, Leisl M. et al. Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug- Resistant Chronic Myeloid Leukemia. Cancer Cell 20, 715-727 (2011).
15. Blank, U., Karlsson, G. and Karlsson, S. Signaling pathways governing stem-cell fate. Blood 111, 492-503 (2008).
16. Chiang, C. et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383, 407-413 (1996).
17. Nusslein-Volhard, C. and Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801 (1980).
18. Jiang, J. and Hui, C. C. Hedgehog signaling in development and cancer. Developmental cell 15, 801-812 (2008).
19. Dierks, C. et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nature medicine 13, 944-951 (2007).
20. Lin, T. L. et al. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. Plos one 5, e15262 (2010).
21. Peacock, C. D. et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 104, 4048-4053 (2007).
22. Queiroz, K. C. et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29, 6314-6322 (2010).
23. Irvine, D. A. and Copland, M. Targeting hedgehog in hematologic malignancy. Blood 119, 2196-2204 (2012).
24. Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779 (2009).
25. Sengupta, A. et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21, 949-955 (2007).
26. Radich, J. P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 2794-2799 (2006).
27. Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer cell 14, 238-249 (2008).
28. Pan, S. et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Medicinal Chemistry Letters 1, 130-134 (2010).
29. Rodon, J. et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clinical cancer research 20, 1900-1909 (2014).
30. Brechbiel, J., Miller-Moslin, K. and Adjei, A. A. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer treatment reviews 40, 750-759 (2014).
31. Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324-334 (2005).
32. The Human Potein Atlas. SHH. Available at: http://www.proteinatlas.org/ENSG00000164690-SHH/tissue. Accessed 18th February 2016.
33. Long, B., Zhu, H., Zhu, C., Liu, T. and Meng, W. Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients. Journal of experimental and clinical cancer research : CR 30, 8 (2011).
34. Wellbrock, J. et al. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clinical cancer research 21, 2388-2398 (2015).
35. Copland, M. et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111, 2843-2853 (2008).
36. Zon, L. I. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 453, 306-313 (2008).
37. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 2, 561-566 (1996).
38. Talpaz, M. et al. Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias. New England Journal of Medicine 354, 2531-2541 (2006).
39. Kantarjian, H. et al. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. New England Journal of Medicine 354, 2542-2551 (2006).
40. Cortes, J. E. et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118, 4567-4576 (2011).
41. Huang, W.-S. et al. Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3- (trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCRABL) Kinase Including the T315I Gatekeeper Mutant. Journal of Medicinal Chemistry 53, 4701-4719 (2010).
42. Holtz, M. S., Forman, S. J. and Bhatia, R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19, 1034-1041 (2005).
43. Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792-3800 (2002).
44. Alonso-Dominguez, J. M. et al. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. American journal of hematology 90, 20-26 (2015).
45. Sadarangani, A. et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. Journal of translational medicine 13, 98 (2015).
46. Gonnissen, A., Isebaert, S. and Haustermans, K. Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget 6, 13899-13913 (2015).
47. Ruiz i Altaba, A., Mas, C. and Stecca, B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends in cell biology 17, 438-447 (2007).
48. Delpuech, O. et al. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Molecular and cellular biology 27, 4917-4930 (2007).
49. Millour, J. et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Molecular cancer therapeutics 10, 1046-1058 (2011).
50. Bockamp, E. O. et al. Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. The Journal of biological chemistry 272, 8781-8790 (1997).
51. Okabe, S., Tauchi, T., Tanaka, Y., Katagiri, S. and Ohyashiki, K. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Stem cells and development 21, 2939-2948 (2012).
52. Katagiri, S. et al. Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant Bcr-Abl1 Positive Leukemia. Clinical cancer research 19, 1422-1432 (2013).
53. Shah, N. P. et al. Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323. Blood 124, abstract 4539 (2014).
54. Ottmann, O. G. et al. Smoothened (SMO) inhibitor LDE225 combined with nilotinib in patients with chronic myeloid leukemia (CML) resistant/intolerant (R/I) to at least 1 prior tyrosine kinase inhibitor: a phase 1B study. Haematologica 100, P231 (2015).
55. Jordan, C. T., Yamasaki, G. and Minamoto, D. High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Experimental Hematology 24, 1347-1355 (1996).
56. Shmittgen, T. D. and L., K. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3, 1101-1108 (2008).
57. Snove, O. and Rossi, J. J. Expressing short hairpin RNAs in vivo. Nature Methods 3, 689-695 (2006).
58. Li, M., Husic, N., Lin, Y. and Snider, B. J. Production of lentiviral vectors for transducing cells from the central nervous system. Journal of visualized experiments 63, e4031 (2012).
59. Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer cell 17, 427-442 (2010).